EUVIMEDEUVIMED entdecken
Multizentrische StudieKontrollierte klinische StudieOpen Access · CC BY-NC-ND 4.0

Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial

Robert W Mutter, Michael A Golafshar, Matthew R Buras, Bryce P Comstock, Maddi Jacobson, Todd DeWees, Nicholas B Remmes, Leah N Francis, Judy C Boughey, Kathryn J Ruddy, Lisa A McGee, Arslan Afzal und 19 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2024.09.019 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Robert W Mutter und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Brachytherapy, Proton Therapy, Photons. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mayo Clinic Arizona, UNC Department of Radiation Oncology, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The optimal approach for partial breast irradiation (PBI) is unknown. We investigated a novel de-intensified 3-fraction PBI regimen for photons, protons, and brachytherapy. METHODS AND MATERIALS: A multicenter nonrandomized controlled trial with the primary outcome of adverse cosmesis at 3 years versus before PBI. Eligibility criteria were age ≥50 years treated with breast-conserving surgery for node-negative estrogen receptor-positive (ER+) invasive breast cancer or any ductal carcinoma in situ (DCIS) measuring ≤2.5 cm. Photon and proton PBI were prescribed 21.9 Gy (relative biological effectiveness) and brachytherapy 21 Gy in 3 fractions. Radiation therapy technique and adjuvant endocrine therapy were selected at physician and patient discretion. RESULTS: Between June 17, 2015, and July 13, 2017, 161 eligible patients were treated with photons (56), protons (49), or brachytherapy (56). Median patient age was 66.8 years. One hundred twenty-six (78.3%) had invasive breast cancer (all ER+) and 35 (21.7%) had DCIS (88.6% ER+). Fifty-four percent of patients with invasive breast cancer and 25.8% of patients with ER+ DCIS initiated and adhered to the prescribed endocrine therapy. The proportion of patients with adverse cosmesis (by trained nurse assessment) was 14.5% at baseline and 2.3% at 3 years (difference, -12.2%; 95% CI, -100% to -6.4%). Adverse cosmesis at the last follow-up, with a median follow-up of 5 years, was 5.7% by nurse assessment, 5.6% by panel assessment of digital photographs, and 5.2% by patient self-report. There were no observed clinically meaningful changes in other patient-reported outcomes, and just 2 grade 2 or higher adverse events, both grade 2, in the brachytherapy cohort. Five-year local recurrence-free survival and progression-free survival were 98.0% and 95.5%, respectively. There were no local recurrences among 60 patients with invasive breast cancer and Ki67 ≤13.25%. CONCLUSIONS: Deintensified 3-day PBI provided favorable disease control, tolerability, and cosmetic outcomes, meeting the prespecified criteria for acceptability. This approach is an attractive option for patients with small node-negative ER+ breast cancer and DCIS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrachytherapyProton TherapyPhotonsCarcinoma, Intraductal, NoninfiltratingHumansFemaleAgedMiddle AgedAged, 80 and overMastectomy, SegmentalRadiotherapy DosageDose Fractionation, Radiation

Autor:innen und Institutionen

  • Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. Electronic address: Mutter.Robert@mayo.edu.
  • Division of Biostatistics and Clinical Trials, Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, Arizona.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
  • Department of Surgery, Mayo Clinic, Rochester, Minnesota.
  • Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
  • Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.

Förderung

  • Mayo Clinic Arizona
  • UNC Department of Radiation Oncology
  • National Cancer Institute

Zitieren

APA

Mutter, R. W., Golafshar, M. A., Buras, M. R., Comstock, B. P., Jacobson, M., DeWees, T., Remmes, N. B., Francis, L. N., Boughey, J. C., Ruddy, K. J., McGee, L. A., Afzal, A., Vallow, L. A., Furutani, K. M., Deufel, C. L., Shumway, D. A., Kim, H., Liu, M. C., Degnim, A. C., …, & Park, S. S. (2025). Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.09.019

Vancouver

Mutter RW, Golafshar MA, Buras MR, Comstock BP, Jacobson M, DeWees T, et al. Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.09.019

BibTeX
@article{Mutter2025,
  author = {Mutter, Robert W and Golafshar, Michael A and Buras, Matthew R and Comstock, Bryce P and Jacobson, Maddi and DeWees, Todd and Remmes, Nicholas B and Francis, Leah N and Boughey, Judy C and Ruddy, Kathryn J and McGee, Lisa A and Afzal, Arslan and Vallow, Laura A and Furutani, Keith M and Deufel, Christopher L and Shumway, Dean A and Kim, Haeyoung and Liu, Minetta C and Degnim, Amy C and Jakub, James W and Vern-Gross, Tamara Z and Wong, William W and Patel, Samir H and Vargas, Carlos E and Stish, Bradley J and Waddle, Mark R and Pafundi, Deanna H and Halyard, Michele Y and Corbin, Kimberly S and Hieken, Tina J and Park, Sean S},
  title = {Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2024.09.019}
}
Kostenlos starten →